Positive News SentimentPositive News BriaCell Therapeutics (BCTX) Stock Price, News & Analysis $4.72 -0.18 (-3.67%) (As of 12/8/2023 08:56 PM ET) Add Compare Share Share Today's Range$4.64▼$4.9750-Day Range$3.79▼$5.9752-Week Range$3.67▼$8.10Volume79,200 shsAverage Volume129,736 shsMarket Capitalization$75.44 millionP/E RatioN/ADividend YieldN/APrice Target$20.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media BriaCell Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside323.7% Upside$20.00 Price TargetShort InterestBearish7.00% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.14) to ($1.05) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.90 out of 5 starsMedical Sector598th out of 942 stocksPharmaceutical Preparations Industry275th out of 424 stocks 3.5 Analyst's Opinion Consensus RatingBriaCell Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $20.00, BriaCell Therapeutics has a forecasted upside of 323.7% from its current price of $4.72.Amount of Analyst CoverageBriaCell Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted7.00% of the float of BriaCell Therapeutics has been sold short.Short Interest Ratio / Days to CoverBriaCell Therapeutics has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.Change versus previous monthShort interest in BriaCell Therapeutics has recently increased by 3.78%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldBriaCell Therapeutics does not currently pay a dividend.Dividend GrowthBriaCell Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BCTX. Previous Next 3.7 News and Social Media Coverage News SentimentBriaCell Therapeutics has a news sentiment score of 1.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for BriaCell Therapeutics this week, compared to 0 articles on an average week.Search Interest2 people have searched for BCTX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BriaCell Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders22.20% of the stock of BriaCell Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 17.33% of the stock of BriaCell Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BriaCell Therapeutics are expected to grow in the coming year, from ($1.14) to ($1.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BriaCell Therapeutics is -3.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BriaCell Therapeutics is -3.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About BriaCell Therapeutics Stock (NASDAQ:BCTX)BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company, which engages in the development of immunotherapies for the treatment of cancer. Its technologies include Bria-IMT and Bria-OTS. The company was founded by Charles L. Wiseman and Isaac B. Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.Read More BCTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BCTX Stock News HeadlinesDecember 6, 2023 | finance.yahoo.comBriaCell Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCSNovember 8, 2023 | finance.yahoo.comBCTX: November 2023 SITC PosterDecember 11, 2023 | Edge On The Street (Ad)The Battery Metal Nobody Told You AboutAccording to McKinsey and Company, the battery storage market is growing rapidly, especially with the transition to clean, renewable energy. Lithium-ion batteries still grab most of the headlines. But analysts now call safe and long-lasting batteries made with vanadium "the future of battery tech." November 4, 2023 | morningstar.comBriaCell Therapeutics Corp Ordinary Shares - New BCTXNovember 1, 2023 | finance.yahoo.comBCTX: Year in ReviewOctober 24, 2023 | morningstar.comBriaCell Therapeutics Corp Ordinary Shares - NewOctober 11, 2023 | finance.yahoo.comBriaCell To Host Virtual Key Opinion Leader Event on Bria-IMT™ Potential in Advanced Metastatic Breast Cancer on October 26, 2023 Featuring Dr. Adam M. Brufsky from University of Pittsburgh School of Medicine and Dr. Saranya Chumsri from Mayo ClinicAugust 31, 2023 | finance.yahoo.comBriaCell Therapeutics Corp. Announces Closing of Plan of Arrangement Spinning Out BriaPro Therapeutics Corp. to Existing ShareholdersDecember 11, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comAugust 31, 2023 | finance.yahoo.comBriaCell Accepts Letter of Intent from Weill Cornell Medicine Outlining Plans to Initiate a Clinical Trial of Bria-IMT™ in High-Risk Early-Stage Triple Negative Breast CancerAugust 28, 2023 | bizjournals.comBriaCell receives court approval to launch spinoff aimed at accelerating cancer drug developmentJuly 10, 2023 | finance.yahoo.comBCTX: Pivotal Study Protocol ClearedJune 28, 2023 | benzinga.comHC Wainwright & Co. Reiterates Buy on BriaCell Therapeutics, Maintains $25 Price TargetJune 27, 2023 | baystreet.caFive Top Companies Fighting for the Treatment of Metastatic Breast CancerJune 27, 2023 | finance.yahoo.comFDA Approves BriaCell’s Pivotal Registrational Study Design in Advanced Metastatic Breast CancerMay 25, 2023 | baystreet.caThere are Positive Developments in the Treatment of Metastatic Breast CancerMay 15, 2023 | baystreet.caFive Impressive Metastatic Cancer Treatment Stocks to Own TodayMay 15, 2023 | finance.yahoo.comBriaCell Announces $4 Million Strategic Investment and Clinical Alliance with Prevail Partners, LLC and Prevail InfoWorks, Inc.April 27, 2023 | finance.yahoo.comBCTX: Posters Galore at AACRApril 10, 2023 | finance.yahoo.comBriaCell Therapeutics (TSE:BCT) Is In A Good Position To Deliver On Growth PlansMarch 30, 2023 | seekingalpha.comBriaCell plans spin-out of some pre-clinical assets into new entityMarch 24, 2023 | finanznachrichten.deUSA News Group: Evolution of Oncology Treatments Giving New Hope to Those Diagnosed with Breast CancerMarch 14, 2023 | finance.yahoo.comA BriaCell Therapeutics Corp. (TSE:BCT) insider increased their holdings by 20% last yearMarch 9, 2023 | finance.yahoo.comBCTX: 82% Survival BenefitFebruary 28, 2023 | seekingalpha.comBCTX BriaCell Therapeutics Corp.January 20, 2023 | finance.yahoo.comLab Notes: Amicus founder gets national honor; Capstan and Code Bio land on list of companies to watchDecember 19, 2022 | finance.yahoo.comBCTX: Down in San AntoneSee More Headlines Receive BCTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BriaCell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/25/2023Today12/11/2023Next Earnings (Estimated)12/13/2023Fiscal Year End7/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BCTX CUSIPN/A CIK1610820 Webwww.briacell.com Phone(604) 921-1810Fax604-921-1898Employees16Year FoundedN/APrice Target and Rating Average Stock Price Target$20.00 High Stock Price Target$20.00 Low Stock Price Target$20.00 Potential Upside/Downside+323.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,300,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-997.24% Return on Assets-62.71% Debt Debt-to-Equity RatioN/A Current Ratio14.96 Quick Ratio14.96 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.24) per share Price / Book-19.67Miscellaneous Outstanding Shares15,982,000Free Float12,434,000Market Cap$75.44 million OptionableNot Optionable Beta1.34 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesWilliam V. WilliamsPresident, Chief Executive Officer & DirectorGadi LevinChief Financial Officer & SecretaryMiguel A. Lopez-LagoChief Scientific OfficerGuiseppe Del PrioreChief Medical OfficerKey CompetitorsLifeVantageNASDAQ:LFVNCorvus PharmaceuticalsNASDAQ:CRVSMediciNovaNASDAQ:MNOVChimerixNASDAQ:CMRXOramed PharmaceuticalsNASDAQ:ORMPView All CompetitorsInsiders & InstitutionsSabby Management LLCBought 712 shares on 11/15/2023Ownership: 0.000%K2 Principal Fund L.P.Bought 24,969 shares on 11/13/2023Ownership: 0.156%K.J. Harrison & Partners IncBought 31,450 shares on 10/31/2023Ownership: 0.414%Concord Wealth PartnersSold 4,500 shares on 10/25/2023Ownership: 0.067%Jamieson BondarenkoBought 28,000 shares on 12/28/2022Total: $128,240.00 ($4.58/share)View All Insider TransactionsView All Institutional Transactions BCTX Stock Analysis - Frequently Asked Questions Should I buy or sell BriaCell Therapeutics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BriaCell Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BCTX shares. View BCTX analyst ratings or view top-rated stocks. What is BriaCell Therapeutics' stock price target for 2024? 1 brokers have issued twelve-month price objectives for BriaCell Therapeutics' stock. Their BCTX share price targets range from $20.00 to $20.00. On average, they predict the company's stock price to reach $20.00 in the next year. This suggests a possible upside of 323.7% from the stock's current price. View analysts price targets for BCTX or view top-rated stocks among Wall Street analysts. How have BCTX shares performed in 2023? BriaCell Therapeutics' stock was trading at $4.37 on January 1st, 2023. Since then, BCTX stock has increased by 8.0% and is now trading at $4.72. View the best growth stocks for 2023 here. When is BriaCell Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, December 13th 2023. View our BCTX earnings forecast. How were BriaCell Therapeutics' earnings last quarter? BriaCell Therapeutics Corp. (NASDAQ:BCTX) released its quarterly earnings data on Wednesday, October, 25th. The company reported ($0.15) EPS for the quarter, topping analysts' consensus estimates of ($0.40) by $0.25. When did BriaCell Therapeutics IPO? (BCTX) raised $15 million in an initial public offering (IPO) on Wednesday, February 24th 2021. The company issued 3,300,000 shares at a price of $4.25-$5.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO. Who are BriaCell Therapeutics' major shareholders? BriaCell Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include K.J. Harrison & Partners Inc (0.41%), K2 Principal Fund L.P. (0.16%), Concord Wealth Partners (0.07%), Sabby Management LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. How do I buy shares of BriaCell Therapeutics? Shares of BCTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:BCTX) was last updated on 12/11/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BriaCell Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.